Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Class |
|---|---|
| Fondazione Italiana Vascolare | OTHER |
Not provided
Not provided
Not provided
Not provided
The study will evaluate the safety and efficacy of subintimal Supera stenting in complex de novo or re-occlusive CTO (TASC C-D) lesions in patients with CLI. This study will be performed based on a rigorous sample size calculation, which will allow us to have the statistical power to validate our conclusions and therefore establish the generalizability of this strategy.
The present study is designed as a prospective, open label, observational study.
The study will collect information about the medical care patients receive during their planned procedure. No additional testing or procedures will be done.
Patients elected for endovascular revascularization with SuperSub strategy will be asked their written consent to the use of their personal data.
Revascularization will be performed as per standard procedure of the sites. After discharge all patients will attend clinic visits at 30 days (±14 days), 6 months (±30 days), 12 months (±30 days) and 24 months (±30 days). Angiographic follow-up will be performed only in symptomatic patients, as clinically indicated and with the aim for a new treatment.
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Stent Peripheral System | Device | Peripheral PTA with Supera Stent implantation |
| Measure | Description | Time Frame |
|---|---|---|
| Primary Patency Rate | Primary Patency is defined as freedom from clinically driven TLR (CD-TLR) defined as repeat percutaneous intervention or surgical bypass graft to treat an angiographic significant restenosis (>50%) at the level of the treated lesion ±10 mm (proximally and/or distally) | 24 months |
| Measure | Description | Time Frame |
|---|---|---|
| Freedom from Restenosis | Freedom from restenosis (diameter stenosis > 50%, determined by peak systolic velocity ratio (PSVR) >2.4 by duplex ultrasonography) | 12 months |
| Freedom from Restenosis |
| Measure | Description | Time Frame |
|---|---|---|
| Cost-efficiency analysis | Cost-efficiency analysis based on the comparison of the yearly procedural related costs and hospital stay(s) between patients treated with the SUPERSUB strategy, vs a propensity-matched historical cohort of patients with the same type of lesions (TASC C-D), treated by PTA alone, after subintimal crossing. | 12 months |
Inclusion Criteria:
General Inclusion Criteria:
Angiographic Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Patients affected by lower extremities artery disease and referred for the endovascular treatment of de novo or re-stenotic lesions (no in stent restenosis) in the femoro-popliteal arteries.
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Maria Salomone, MD | EndoCore Lab | Study Director |
| Mariano L Palena, MD | Casa di Cura Abano Terme | Study Chair |
| Larry J Diaz, MD,PhD | Metro Health Hospital | Study Chair |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Metro Health Hospital | Wyoming | Michigan | 49519 | United States | ||
| Instituto Medico CENICLAR, Unidad Sanatorio de la Mujer |
Not provided
Not provided
Not provided
Not provided
Freedom from restenosis (diameter stenosis > 50%, determined by peak systolic velocity ratio (PSVR) >2.4 by duplex ultrasonography)
| 24 months |
| Composite of All Major Adverse Events | Incidence of the composite of all Major Adverse Events | 12 Months |
| Composite of All Major Adverse Events | Incidence of the composite of all Major Adverse Events | 24 Months |
| Incidence of Major Adverse Events | Incidence of Major Adverse Events | 12 months |
| Incidence of Major Adverse Events | Incidence of Major Adverse Events | 24 months |
| Stent integrity assessment | Stent integrity assessment will be evaluated with two oblique opposite projection X-ray images | 12 months |
| Stent integrity assessment | Stent integrity assessment will be evaluated with two oblique opposite projection X-ray images | 24 months |
| Primary Sustained Clinical Improvement | Clinical Improvement as assessed by Rutherford Class changes | 6,12 and 24 months vs baseline |
| Quality of Life (EQ-5D-5L Questionnaire) | Quality of Life improvement as assessed by EQ-5D-5L Questionnaire Parameters [Mobility, Self-Care, Usual Activities, Pain/Discomfort, Anxiety/Depression] Values [(1) No Problems, (2) Slight Problems, (3) Moderate Problems, (4) Severe Problems, (5) Unable to] Value [1 - Best score, Value 5 - Worse Score] | 6 months |
| Quality of Life improvement (SF12 Questionnaire) | Quality of Life improvement as assessed by SF12 Questionnaire Parameters [Overall Health, Physical health, Role and Physical health, Role and Mental health, Mental health] Values for Overall Health [ 1-Excellent, 2- Very Good, 3-Good, 4-Acceptable, 5-Poor] Values for Role and Physical health [ 1-Very limiting, 2-Partially limiting, 3-Not limiting] Values for Physical health [ 1-yes, 2-no], [1- best score] , [2-worse score] Values for Role and Mental health [ 1-yes, 2-no], [1- best score] , [2-worse score] Values for Mental Health [ 1-Excellent, 2- Very Good, 3-Good, 4-Acceptable, 5-Poor] | 6 months |
| Quality of Life (EQ-5D-5L Questionnaire) | Quality of Life improvement as assessed by EQ-5D-5L Questionnaire Parameters [Mobility, Self-Care, Usual Activities, Pain/Discomfort, Anxiety/Depression] Values [(1) No Problems, (2) Slight Problems, (3) Moderate Problems, (4) Severe Problems, (5) Unable to] Value 1 - Best score, Value 5 - Worse Score | 12 months |
| Quality of Life improvement (SF12 Questionnaire) | Quality of Life improvement as assessed by SF12 Questionnaire Parameters [Overall Health, Physical health, Role and Physical health, Role and Mental health, Mental health] Values for Overall Health [ 1-Excellent, 2- Very Good, 3-Good, 4-Acceptable, 5-Poor] Values for Role and Physical health [ 1-Very limiting, 2-Partially limiting, 3-Not limiting] Values for Physical health [ 1-yes, 2-no], [1- best score] , [2-worse score] Values for Role and Mental health [ 1-yes, 2-no], [1- best score] , [2-worse score] Values for Mental Health [ 1-Excellent, 2- Very Good, 3-Good, 4-Acceptable, 5-Poor] | 12 months |
| Quality of Life (EQ-5D-5L Questionnaire) | Quality of Life improvement as assessed by EQ-5D-5L Questionnaire Parameters [Mobility, Self-Care, Usual Activities, Pain/Discomfort, Anxiety/Depression] Values [(1) No Problems, (2) Slight Problems, (3) Moderate Problems, (4) Severe Problems, (5) Unable to] Value 1 - Best score, Value 5 - Worse Score | 24 months |
| Quality of Life improvement | Quality of Life improvement as assessed by SF12 Questionnaire Parameters [Overall Health, Physical health, Role and Physical health, Role and Mental health, Mental health] Values for Overall Health [ 1-Excellent, 2- Very Good, 3-Good, 4-Acceptable, 5-Poor] Values for Role and Physical health [ 1-Very limiting, 2-Partially limiting, 3-Not limiting] Values for Physical health [ 1-yes, 2-no], [1- best score] , [2-worse score] Values for Role and Mental health [ 1-yes, 2-no], [1- best score] , [2-worse score] Values for Mental Health [ 1-Excellent, 2- Very Good, 3-Good, 4-Acceptable, 5-Poor] | 24 months |
| Amputation Rates | Major and Minor amputations | 1 month |
| Amputation Rates | Major and Minor amputations | 6 months |
| Amputation Rates | Major and Minor amputations | 12 months |
| Amputation Rates | Major and Minor amputations | 24 months |
| Cost-efficiency analysis |
Cost-efficiency analysis based on the comparison of the yearly procedural related costs and hospital stay(s) between patients treated with the SUPERSUB strategy, vs a propensity-matched historical cohort of patients with the same type of lesions (TASC C-D), treated by PTA alone, after subintimal crossing. |
| 24 months |
| Technical success | Technical success defined as achievement of a final in-lesion residual diameter stenosis of ≤30% as determined by the angiographic core lab | 1 month |
| Clinical success | Clinical success defined as technical success without the occurrence of major adverse events | 1 month |
| Procedural success | Procedural success defined as lesion success without the occurrence of major adverse events | 1 month |
| ABI index or transcutaneous oxymetry (TcPO2) improvement | Improve in the ABI index or transcutaneous oxymetry (TcPO2) | 6 and 12 months vs baseline |
| Rosario |
| Santa Fe Province |
| S2000 |
| Argentina |
| Ospedale di Avezzano | Avezzano | AQ | 67051 | Italy |
| Clinica San Michele | Maddaloni | CE | 81024 | Italy |
| A.O.U. Policlinico Vittorio Emanuele | Catania | CT | 95123 | Italy |
| A.O. Cardinale Panico | Tricase | LE | 73039 | Italy |
| Casa di Cura Abano Terme | Abano Terme | Padova | 35031 | Italy |
| A.O.U. Santa Maria della Misericordia | Perugia | PG | 06129 | Italy |
| Policlinico Tor Vergata | Roma | RM | 00133 | Italy |
| A.O. San Giovanni Addolorata | Roma | RM | 00184 | Italy |
| A.O.U. di Sassari | Sassari | SS | 07100 | Italy |
| Ospedale San Antonio Abate | Erice | TP | 91016 | Italy |
| Azienda Ospedaliera Santa Maria di Terni | Terni | TR | 05100 | Italy |
| AORN Antonio Cardarelli | Naples | 80131 | Italy |
| London North West HealthCare NHS Trust | London | England | HA1 3UJ | United Kingdom |